Navigating Small-Cap Biotech ETFs: Five Focused Investment Vehicles Worth Considering

Exchange-traded funds have revolutionized how investors access diversified sectors. When it comes to small-cap biotech ETF opportunities, these funds enable exposure to multiple biotechnology companies through a single, manageable vehicle. This approach offers a safer entry point compared to selecting individual biotech stocks, as the impact of any single company’s underperformance becomes diluted across the broader portfolio. The following analysis examines five small-cap biotech ETFs based on data current as of late February 2026, focusing specifically on funds with total assets under management below US$100 million.

Leveraged Biotech Strategies for Bullish Investors

ProShares Ultra NASDAQ Biotechnology ETF (NASDAQ:BIB)

With approximately US$89.54 million in assets, this small-cap biotech ETF stands out as the largest among the group. Established in April 2010, BIB targets investors seeking magnified exposure to the pharmaceutical sector through a 2x leveraged structure that tracks the NASDAQ Biotechnology Index daily. The fund’s design makes it particularly suited for traders with bullish short-term outlooks rather than buy-and-hold investors. Its 263 portfolio holdings are anchored by major positions in Gilead Sciences (6.78%), Amgen (6.23%), and Vertex Pharmaceuticals (6.17%). However, financial advisors consistently caution that the leverage mechanism introduces significant volatility—making it inappropriate for risk-averse investors or those pursuing long-term buy-and-hold strategies.

Inverse ETFs: Positioned for Downturns

Direxion Daily S&P Biotech Bear 3X Shares (ARCA:LABD)

This small-cap biotech ETF takes the opposite approach, providing 3x inverse daily exposure to the S&P Biotechnology Select Industry Index. With US$68.18 million in assets under management, LABD profits when biotech stocks decline and loses value during rallies. Unlike traditional biotech funds that hold underlying stocks, LABD achieves its objective through financial derivatives and futures contracts. This structure makes it explicitly a short-term trading instrument, unsuitable for investors with multi-year horizons. The high leverage combined with daily rebalancing creates compounding effects that can amplify losses during extended market recoveries.

Thematic Biotech Focus: Emerging Health Priorities

Tema Heart and Health ETF (NASDAQ:HRTS)

Introduced in November 2023, this small-cap biotech ETF reflects evolving market priorities by focusing on companies addressing diabetes, obesity, and cardiovascular disease. The fund underwent two rebrands in 2026—first from a cardiovascular-specific mandate to a GLP-1 focused strategy, then to its current health and heart designation—underscoring the rapid shifts in biotech investment themes. HRTS manages approximately US$56.55 million with 46 holdings weighted toward large-cap (75%) and mid-cap (22%) positions, predominantly US-listed companies. Top positions include Eli Lilly (10.04%), Roche Holding (5.42%), and Johnson & Johnson (4.8%), reflecting major players leading growth in metabolic disease treatments.

Genomics and Precision Medicine Innovation

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

This small-cap biotech ETF zeroes in on the genomics revolution, tracking the Solactive Genomics Index with a focus on gene editing, sequencing, computational genomics, and genetic medicine developers. With US$51.53 million in AUM, the fund holds 50 stocks concentrated in pharmaceuticals and life sciences (90% of portfolio). Leading holdings include Moderna (6.33%), Arrowhead Pharmaceuticals (6.14%), and Praxis Precision Medicines (5.98%), positioning investors at the frontier of precision medicine development. This specialized approach appeals to investors convinced that genomic breakthroughs will drive the sector’s next growth phase.

Equal-Weighted Biotech Products: An Alternative Approach

Virtus LifeSci Biotech Products ETF (ARCA:BBP)

Rounding out the selection is this small-cap biotech ETF with US$44.8 million in assets, launched in December 2014. Rather than market-cap weighting, BBP employs an equal-weighted approach targeting US-listed biotech companies that have achieved at least one FDA-approved drug therapy. This methodology, rebalanced semi-annually, provides a different risk-return profile by limiting individual company concentration while emphasizing firms with tangible commercial validation. Notable holdings include ImmunityBio (3.98%), Mirum Pharmaceuticals (2.4%), and Moderna (2.16%), creating a portfolio spanning from emerging innovators to established players.

Making the Right Selection for Your Strategy

Choosing among small-cap biotech ETFs requires matching fund characteristics with your investment timeline and risk tolerance. Leveraged instruments like BIB suit tactical traders, while inverse structures like LABD appeal to market timers anticipating corrections. Thematic funds such as HRTS and GNOM offer sector-specific conviction plays, whereas products-focused vehicles like BBP emphasize fundamental commercialization milestones. Each small-cap biotech ETF carves out a distinct niche—the key lies in understanding whether the fund’s mechanics and focus align with your portfolio objectives and time horizon.